TABLE 3.
Prevalence of baseline polymorphisms among DAA-naive patients
| HCV subtypea | Target | Baseline polymorphismb | % of patients with baseline polymorphism (no. of patients with polymorphism/total no. of patients sequenced) |
||||
|---|---|---|---|---|---|---|---|
| Total | Without cirrhosisc |
With compensated cirrhosisc |
|||||
| TNd | IFN-TEd | TNd | IFN-TEd | ||||
| 1a | NS3 | Q80K/L | 50.0 (2/4) | 66.7 (2/3) | |||
| Any | 50.0 (2/4) | 66.7 (2/3) | (0/1) | ||||
| NS5A | M28V | 25.0 (1/4) | 100 (1/1) | ||||
| Q30H | 25.0 (1/4) | 33.3 (1/3) | |||||
| Y93F | 25.0 (1/4) | 33.3 (1/3) | |||||
| Any | 50.0 (2/4) | 33.3 (1/3) | 100 (1/1) | ||||
| 1b | NS3 | V36L | 0.6 (1/162) | 3.8 (1/26) | |||
| T54S | 3.1 (5/162) | 2.2 (2/89) | 5.7 (2/35) | 3.8 (1/26) | |||
| V55I | 1.9 (3/162) | 1.1 (1/89) | 7.7 (2/26) | ||||
| Y56F | 38.9 (63/162) | 43.8 (39/89) | 31.4 (11/35) | 30.8 (8/26) | 41.7 (5/12) | ||
| Q80K/L/R | 18.5 (30/162) | 15.7 (14/89) | 25.7 (9/35) | 23.1 (6/26) | 8.3 (1/12) | ||
| D168E | 1.2 (2/162) | 1.1 (1/89) | 3.8 (1/26) | ||||
| Any | 50.6 (82/162) | 49.4 (44/89) | 51.4 (18/35) | 53.8 (14/26) | 50.0 (6/12) | ||
| NS5A | Q24K/R | 8.1 (13/161) | 6.8 (6/88) | 5.7 (2/35) | 15.4 (4/26) | 8.3 (1/12) | |
| L28M | 8.1 (13/161) | 6.8 (6/88) | 5.7 (2/35) | 15.4 (4/26) | 8.3 (1/12) | ||
| R30H/L/Q | 11.8 (19/161) | 13.6 (12/88) | 5.7 (2/35) | 19.2 (5/26) | |||
| L31M | 3.7 (6/161) | 3.4 (3/88) | 2.9 (1/35) | 7.7 (2/26) | |||
| P58Q/R/S/T | 7.5 (12/161) | 9.1 (8/88) | 8.6 (3/35) | 3.8 (1/26) | |||
| A92E/P/T/V | 8.1 (13/161) | 5.7 (5/88) | 11.4 (4/35) | 3.8 (1/26) | 25.0 (3/12) | ||
| Y93H | 18.0 (29/161) | 20.5 (18/88) | 14.3 (5/35) | 19.2 (5/26) | 8.3 (1/12) | ||
| Any | 42.9 (69/161) | 43.2 (38/88) | 37.1 (13/35) | 50.0 (13/26) | 41.7 (5/12) | ||
| 2a | NS3 | L36I/M | 4.0 (3/75) | 5.3 (3/57) | |||
| Y56F | 4.0 (3/75) | 3.5 (2/57) | 20.0 (1/5) | ||||
| D168E | 1.3 (1/75) | 1.8 (1/57) | |||||
| Any | 9.3 (7/75) | 10.5 (6/57) | (0/11) | (0/2) | 20.0 (1/5) | ||
| NS5A | T24A/S | 6.4 (5/78) | 5.3 (3/57) | 25.0 (1/4) | 16.7 (1/6) | ||
| F28C/L | 2.6 (2/78) | 3.5 (2/57) | |||||
| L31M | 92.3 (72/78) | 93.0 (53/57) | 100 (11/11) | 75.0 (3/4) | 83.3 (5/6) | ||
| P58S | 7.7 (6/78) | 7.0 (4/57) | 25.0 (1/4) | 16.7 (1/6) | |||
| C92N/S | 3.8 (3/78) | 5.3 (3/57) | |||||
| Any | 94.9 (74/78) | 96.5 (55/57) | 100 (11/11) | 75.0 (3/4) | 83.3 (5/6) | ||
| 2b | NS3 | Y56F | 5.4 (2/37) | 16.7 (1/6) | 11.1 (1/9) | ||
| Any | 5.4 (2/37) | (0/21) | 16.7 (1/6) | 11.1 (1/9) | (0/1) | ||
| NS5A | L28F | 16.2 (6/37) | 14.3 (3/21) | 22.2 (2/9) | 100 (1/1) | ||
| M31I/L/V | 16.2 (6/37) | 23.8 (5/21) | 16.7 (1/6) | ||||
| P58S | 5.4 (2/37) | 4.8 (1/21) | 11.1 (1/9) | ||||
| Any | 35.1 (13/37) | 38.1 (8/21) | 16.7 (1/6) | 33.3 (3/9) | 100 (1/1) | ||
| 3a | NS3 | A166S/T | 28.6 (2/7) | 33.3 (1/3) | 33.3 (1/3) | (0/1) | |
| NS5A | A30K | 14.3 (1/7) | 33.3 (1/3) | ||||
| Y93H | 14.3 (1/7) | 33.3 (1/3) | |||||
| Any | 28.6 (2/7) | 33.3 (1/3) | 33.3 (1/3) | (0/1) | |||
| 3b | NS3 | Any | (0/4) | (0/1) | (0/2) | (0/1) | |
| NS5A | V31M | 100 (4/4) | 100 (1/1) | 100 (2/2) | 100 (1/1) | ||
| 3k | NS5A | G92E | 100 (1/1) | 100 (1/1) | |||
HCV subtype was determined by phylogenetic analysis of NS3/4A and/or NS5A sequences.
Polymorphisms relative to the subtype-specific reference sequence at amino acid positions important for the inhibitor class, positions 36, 43, 54, 55, 56, 80, 155, 156, 166 (GT3 only), and 168 in NS3 and positions 24, 28, 30, 31, 32, 58, 92, and 93 in NS5A, at a 15% detection threshold, were included in the analysis.
GT1- and GT2-infected patients without cirrhosis received 8 weeks of treatment. GT1- and GT2-infected patients with compensated cirrhosis and GT3-infected patients with or without cirrhosis received 12 weeks of treatment.
IFN-TE, treatment experienced with an interferon-containing regimen but DAA naive; TN, treatment naive.